Objective To evaluate the maternal–fetal outcomes of CAB-induced pregnancies in patients with prolactinoma in a large cohort. Methods The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study, Results We included 194 women with a mean age of 31 (17–45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. In 233 pregnancies, CAB was withdrawn in 89%, after pregnancy confrmation. Symptoms related to tumor growth occurred in 25 cases, more frequently in macroadenomas. The overall miscarriage rate was 11%, a...
Macroprolactinomas are rarely seen in women, and pregnancy is a risk factor for tumor growth. More s...
Giant prolactinomas are a rare entity; during pregnancy, the risk for complications associated with ...
Bromokriptin ve kabergolin prolaktinoma tedavisinde kullanılan en yaygın dopamin agonistleridir. Dop...
To evaluate the maternal–fetal outcomes of CAB-induced pregnancies in patients with prolactinoma in ...
Os adenomas hipofisários secretores de prolactina (prolactinomas) são causa frequente de infertilida...
Prolactinoma is a common cause of infertility in young women and treatment with dopamine agonists (D...
OBJECTIVE: Cabergoline is a dopamine agonist used to treat hyperprolactinaemia. Because hyperprolact...
The current survey study investigated the recurrence rate of hyperprolactinemia after cabergoline (C...
Abstract Background We assessed the safety of Cabergoline therapy during pregnancy in a lady with hy...
Management of prolactinoma in pregnancy is a big challenge for the treating obstetrician as prolacti...
Abstract Context: Data concerning the safety for pregnancy of cabergoline treatment in hyperprolacti...
We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies r...
Background and objective: Prolactinoma is an uncommon cause of amenorrhea and subfertility in female...
Background: We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprola...
We report a particular case of a spontaneously occurring pregnancy in a long-term amenorrheic patien...
Macroprolactinomas are rarely seen in women, and pregnancy is a risk factor for tumor growth. More s...
Giant prolactinomas are a rare entity; during pregnancy, the risk for complications associated with ...
Bromokriptin ve kabergolin prolaktinoma tedavisinde kullanılan en yaygın dopamin agonistleridir. Dop...
To evaluate the maternal–fetal outcomes of CAB-induced pregnancies in patients with prolactinoma in ...
Os adenomas hipofisários secretores de prolactina (prolactinomas) são causa frequente de infertilida...
Prolactinoma is a common cause of infertility in young women and treatment with dopamine agonists (D...
OBJECTIVE: Cabergoline is a dopamine agonist used to treat hyperprolactinaemia. Because hyperprolact...
The current survey study investigated the recurrence rate of hyperprolactinemia after cabergoline (C...
Abstract Background We assessed the safety of Cabergoline therapy during pregnancy in a lady with hy...
Management of prolactinoma in pregnancy is a big challenge for the treating obstetrician as prolacti...
Abstract Context: Data concerning the safety for pregnancy of cabergoline treatment in hyperprolacti...
We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies r...
Background and objective: Prolactinoma is an uncommon cause of amenorrhea and subfertility in female...
Background: We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprola...
We report a particular case of a spontaneously occurring pregnancy in a long-term amenorrheic patien...
Macroprolactinomas are rarely seen in women, and pregnancy is a risk factor for tumor growth. More s...
Giant prolactinomas are a rare entity; during pregnancy, the risk for complications associated with ...
Bromokriptin ve kabergolin prolaktinoma tedavisinde kullanılan en yaygın dopamin agonistleridir. Dop...